FDA Approves Abbott AFib Device
Abbott Secures FDA Approval For New Dual-Energy Catheter To Treat Atrial Fibrillation
Anonymous
Key Points
1
Atrial fibrillation affects an estimated 10.5 million people in the United States and can significantly increase the risk of stroke.
2
The FlexPulse IDE study supporting the FDA approval evaluated the device in patients with paroxysmal atrial fibrillation, according to Abbott’s announcement.
3
TactiFlex Duo is designed to work alongside Abbott’s Advisor HD Grid X mapping catheter and ViewFlex X ICE intracardiac echocardiography catheter with the EnSite Echo Module, extending its integration across Abbott’s electrophysiology portfolio.
4
Uri Yaron, Abbott’s senior vice president of electrophysiology, said the device was an important advancement as the company builds a comprehensive electrophysiology portfolio spanning diagnosis, mapping, intracardiac ultrasound imaging and treatment of complex arrhythmias.
Abbott Laboratories received FDA approval for its TactiFlex Duo Ablation Catheter, a dual-energy device designed to treat challenging cases of atrial fibrillation, according to Fierce Biotech. The catheter combines pulsed field ablation and radiofrequency energy, giving doctors flexibility to use one, the other, or both during procedures to target abnormal heart rhythms while protecting surrounding tissue.
The approval, supported by safety data from the FlexPulse IDE study, marks Abbott's fifth major electrophysiology approval in just over a year, Medical Device Network reported. The device integrates with Abbott's EnSite X EP System for real-time 3D cardiac mapping and lesion assessment, with procedures expected to begin within weeks across the United States.
Why This Dual-Energy Approach Matters
The TactiFlex Duo gives physicians two distinct energy options in a single catheter. Pulsed field ablation uses electrical energy to create lesions, while radiofrequency energy delivers heat. G-Medtech noted doctors can now choose which energy type works best for each patient's unique anatomy, or combine both methods during one procedure for optimal results.
This flexibility addresses a major clinical challenge: some AFib patients have tissue locations or scar patterns that respond better to one energy type than another. By offering both tools in one device, Abbott reduces the need for physicians to switch catheters mid-procedure, potentially shortening treatment time and improving patient outcomes.
The AFib Crisis Affecting Millions of Americans
Atrial fibrillation affects an estimated 10.5 million people in the United States and significantly increases stroke risk. The condition causes irregular heart rhythms that can lead to blood clots, heart failure, and serious complications if left untreated. Current ablation procedures aim to eliminate the faulty heart tissue causing these dangerous rhythms.
The FlexPulse IDE study tested TactiFlex Duo specifically in patients with paroxysmal atrial fibrillation—episodes of rapid, irregular heartbeats that start and stop on their own, MedTech Dive reported. This patient population often requires highly targeted ablation to prevent AFib episodes from recurring.
Expanding Abbott's Electrophysiology Arsenal
The TactiFlex Duo plugs into Abbott's growing electrophysiology platform, which already includes the Advisor HD Grid X mapping catheter and ViewFlex X intracardiac echocardiography catheter. These tools work together within the EnSite Echo Module to provide comprehensive diagnosis, mapping, imaging, and treatment for complex arrhythmias.
Uri Yaron, Abbott's senior vice president of electrophysiology, called the approval an important advancement in building a complete portfolio for arrhythmia care. With five major EP approvals in over a year, Abbott is rapidly expanding its position in cardiac ablation, a high-growth segment of the medical device market.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
40
Reach
53
A
AnonymousAuthor
